

Special Issue

Novel Anticancer Strategies (Volume II)

Message from the Guest Editor

In this Special Issue of *Pharmaceutics*, novel anticancer strategies with reduced toxicity and improved therapeutic indices, presented in original articles and comprehensive reviews highlighting the latest advances, are welcome. These strategies would suggest prospects for optimizing cancer therapies, hopefully with tremendous clinical value in the near future. Toward these aims, we encourage submissions that focus on the development and validation of novel anticancer approaches, which include, but are not limited to, ligand-/receptor-based targeting, controlled drug delivery, gene delivery, targeted anticancer prodrug and conjugate (photoactivatable caged prodrugs, ADEPT, ADAPT, ADCs), magnetic and ultrasound-mediated drug targeting, and cancer stem cell therapy that explores the targeting of signaling cascades and the tumor microenvironment.

- cancer therapy
- drug delivery
- drug carriers
- targeted therapy
- prodrugs (photoactivatable caged prodrugs, ADEPT, and ADAPT)
- antibody drug conjugates (ADCs)
- controlled drug release
- immunotherapy
- gene therapy (GDEPT)
- stem cell therapy

Guest Editor

Dr. Hassan Bousbaa

UNIPRO—Unidade de Investigação em Patologia e Reabilitação Oral,
IUCS, CESPU, Rua Central de Gandra, 1317, 4585-116 Gandra PRD,
Portugal

Deadline for manuscript submissions

closed (30 May 2022)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/70542

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).